✦ LIBER ✦

Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy

✍ Scribed by Stefan C. Grant; Mark G. Kris; Richard J. Gralla; Rebecca A. Clark; Leslie B. Tyson

Publisher: Springer
Year: 1993
Tongue: English
Weight: 314 KB
Volume: 31
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00685032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose-ranging antiemetic evaluation of th

Dose-ranging antiemetic evaluation of the serotonin antagonist rg 12915 in patients receiving anticancer chemotherapy

✍ Lorraine Baltzer; Mark G. Kris; Leslie B. Tyson; James R. Rigas; Katherine M. W. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB

Background. RG 12915 is a potent, selective 5-HT3 receptor antagonist with a biologic half-life of 31-20 hours. RG 12915 prevents cisplatin-induced emesis in ferrets at doses of 0.03 mg/kg. Animal toxicology studies permitted safe testing in humans at doses of up to 2.0 mg/kg. This dose-ranging tria

Dose-ranging antiemetic evaluation of th

Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy

✍ Katherine M. W. Pisters; Mark G. Kris; Leslie B. Tyson; Rebecca A. Clark; Richar 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

Dose-ranging evaluation of the antiemeti

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide

✍ Paul J. Hesketh; David R. Gandara; Ann M. Hesketh; Anna Facada; Edith A. Perez; 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 619 KB